The health and supplement industries are constantly developing. Thanks to the ever-changing supplement landscape, it has become tough to separate genuine products from crazes offering not any benefits to consumers. Lately, peptides have come out as a new member of the supplement market. Peptides are naturally occurring compounds that are present in every living cell.
As they are crucial to all living things, peptides are the conjunction of more than two amino acids and serve numerous biological purposes. A good example is ARA 290 peptide that offers an efficient alternative to improve symptoms, manage pain and promote healing, unlike other supplements. In this article, you will get to know more about this peptide, its benefits, and research studies.
ARA 290 Peptide Origins
The erythropoietin (EPO) is the origin of the ARA 290 peptide. For decades, people have been using erythropoietin as it can facilitate red blood cell production inside the bone marrow. This peptide promotes cell survival, can change a person’s blood pressure, and form a neuroprotective effect. The peptide offers neuroprotective effects and pain relief, even when it does not evoke red blood cell production.
The peptide is also well-known for its potential to encourage patients having chronic diabetes. However, this property still needs further research. On the other hand, this peptide is under study as a possible treatment for systemic lupus erythematosus.
The full extent of the peptide is still under research. But, this peptide can reduce inflammatory pathways of the user with the help of paracrine signaling. The benefits of this peptide also have connections to improved cholesterol numbers and a decrease in HbA1c. However, studies with these claims are still in their trial stages.
Perhaps the most attractive possibility of this peptide is stimulating natural wound repair processes and its ability to decrease neuropathic symptoms. It is an exhilarating treatment option for people with diabetes-related alignments and chronic neuropathic pain. It is also safe to combine the peptide with other peptides with healing properties such as BPC- 157.
ARA 290 Research
Numerous researches are going on to explore its potential in different aspects. The research on ARA 290 includes:
- Blood vessel health
- Reducing inflammatory cytokines
- Tissue protection
- Pain perception
- Immune system
- Orphan drug
Research in mice reveals that the peptide can shield endothelial colony-forming cells against inflammation damage. In order to do so, the peptide allows endothelial colony-forming cells to rebuild and repair blood vessels and prolongs cell survival. The research study also seems to show that it encourages the homing ability of ECFCs, and helps these cells to a better target area in need of repairs of the vasculature.
Helps with Regeneration, Wound Healing, and Scar Formation
Research in mice signifies that peptides like this can help foster the existence of transplanted islet cells by deterring macrophage activation. It also protects from natural inflammation by intervening through immune system regulation and tissue protection. By not stimulating a few effects of EPO and binding TPR, ARA 290 cuts back on the level of damaging inflammation cytokines and helps to minimize apoptosis. The net results show progress in tissue regeneration and tissue protection.
These features lead to low mortality and morbidity, fast post-injury recovery functions, quick wound healing, and less scar formation.
While the prime focus of this peptide is to control neuropathic pain, it also has the ability to modulate its immune properties and can stimulate wound repair. The peptide is also likely a means of protecting vasculature during ischemic insult.
Currently, it is in its second and third phases of trials for treating Sarcoid neuropathy and diabetic neuropathy. There are also possibilities of using this peptide for treating the pain syndromes of Celiac disease, multiple sclerosis, HIV, systemic lupus erythematosus, and many others.